

2015 Strategies in the German Hospital Tumor Marker Testing Market

https://marketpublishers.com/r/20E552ADB8AEN.html

Date: February 2015 Pages: 530 Price: US\$ 3,080.00 (Single User License) ID: 20E552ADB8AEN

Abstracts

This new report from VPGMarketResearch contains 530 pages, 40 tables, and presents a comprehensive analysis of the German hospital tumor marker testing market, including:

Major issues pertaining to the German hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Test volume and sales forecasts for 40 tumor markers performed in German hospitals.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in



R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 530 pages and 40 tables



Contents

Introduction

Worldwide Market and Technology Overview

- A. Cancer Statistics and Etiology
- 1. BREST CANCER
- 2. LUNG CANCER
- 3. COLON AND RECTUM CANCER
- 4. PROSTATE CANCER
- 5. STOMACH CANCER
- 6. LEUKEMIA
- 7. LYMPHOMA
- 8. ORAL CANCER
- 9. SKIN CANCER
- **10. UTERINE CANCER**
- 11. OVARIAN CANCER
- 12. BLADDER CANCER
- B. Major Current And Emerging Cancer Diagnostic Tests
- 1. INTRODUCTION
- 2. TUMOR MARKER CLASSIFICATION
- 3. ACTH
- 4. ALPHA-FETOPROTEIN (AFP)
- 5. BETA-2 MICROGLOBULIN
- 6. CA 15-3/27.29
- 7. CA 19-9
- 8. CA-125
- 9. CALCITONIN
- 10. CARCINOEMBRIONIC ANTIGEN (CEA)
- 11. ESTROGEN AND PROGESTERONE RECEPTORS
- 12. FERRITIN
- 13. GASTRIN
- 14. HUMAN CHORIONIC GONADOTROPIN (HCG)
- 15. INSULIN
- 16. NSE
- 17. OCCULT BLOOD
- 18. PAP SMEAR/HPV
- 19. PROSTATIC ACID PHOSPHATASE (PAP)



20. PROSTATE-SPECIFIC ANTIGEN (PSA) 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC) 22. T AND B LYMPHOCYTES 23. TDT 24. THYROGLOBULIN 25. TISSUE POLYPEPTIDE ANTIGEN (TPA) 26. BIOCHEMICAL TUMOR MARKERS ADA **B-Protein** PNP 5'-Nucleotidase 27. ONCOGENES Abl/abl-bcr AIB1 BCL-2 BRCA1 **CD44** C-fos C-myb C-myc **CYP-17** Erb-B HPC1 N-myc P40 P51 P53 PIK3CA PTI-1 Ras Reg Sis Src 28. POLYPEPTIDE GROWTH FACTORS **Basic Fibroblast Growth Factor** Beta-TGF Cachectin (TNT) Calmodulin **ECFR**



Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) **Ornithine Decarboxylase** Transferrin Transforming Growth Factor-Alpha **29. ECTOPIC HORMONES 30. COLONY STIMULATING FACTORS 31. LYMPHOKINES** Alpha-Interferon **B Cell Growth Factors** B Cell Growth Factor (BCGF) Gamma-Interferon Interleukin-1 (IL-1) Macrophage Activating Factor **32. IMMUNOHISTOCHEMICAL STAINS 33. EMERGING TUMOR MARKERS** N-Acetylglucosamine Actin Alpha-Actin **Antineuronal Antibodies** 7B2 B72.3 Bax BCD-F9 BLCA-4 Blood Group Antigens A,B,H CA CA 72-4/TAG-72 CA CA-242 CA-549 CAM CAR-3 Cathepsin-D Chromogranin A and B Cluster 1 Antigen Cluster-5/5A Antigen CTA CU18



DR-70 DU-PAN-2 **Endometrial Bleeding Associated Factor** Endostatin Epithelial Membrane Antigen Feulgen Hydrolysis Fibronectin FSH (1->3)-L-fucosyltransferase Gastrin-Releasing Peptide (GRP) GDCFP-15 Glucagon Glycoamines H23 Her-2 Human Carcinoma Antigen HPA HSP27 Intermediate Filaments Cytokeratins/CK18/Cyfra 21-1 Desmin **Gliofibrillary Acid Protein Neurofilaments** Vimentin KA **Kinases KP16D3** LAI Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA)



Multiple Tumor Suppressor Myosin **NEA-130** NMP22 OA-519 **Opiod Peptides** P-glycoprotein Pancreatic Oncofetal Antigen (POA) Placental Lactogen **PR92** Proliferative Index, Ki-67 Px **RB** Inactivation/Deletion Ret SCCL Selectin Sialic Acid Sialyl SSEA-1/SLX **SN10** Somatostatin **TA-90** TABA Tachykinin TAG TPS Troponin Tubulin VCAM VEGF Villen C. Instrumentation Review And Market Needs 1. ABBOTT AXSYM 2. ABBOTT ARCHITECT C4000 3. ABBOTT ARCHITECT I200 SERIES 4. ABBOTT ARCHITECT CI820 SYSTEM **5. BECKMAN COULTER UNICEL SERIES** 6. BECKMAN COULTER ACCESS 7. BINDING SITE ESP600 8. BIOMERIEUX MINI VIDAS



9. CAROLINA CHEMISTRIES BIOLIS 24I

- 10. DIASORIN LIAISON
- 11. HORIBA ABX PENTRA
- 12. INVERNESS DS2
- 13. J&J VITROS ECI/ECIQ
- 14. J&J VITROS 3600
- 15. J&J VITROS 5600
- 16. OLYMPUS AU5400
- 17. OLYMPUS AU3000I
- 18. OLYMPUS AU2700
- **19. ROCHE MODULAR ANALYTICS**
- 20. ROCHE COBAS INTEGRA
- 21. ROCHE COBAS INTEGRA 40 PLUS
- 22. ROCHE ELECSYS
- 23. ROCHE COBAS C311
- 24. SIEMENS ADVIA CENTAUR
- 25. SIEMENS DIMENSION
- 26. SIEMENS DIMENSION RXL MAX
- 27. SIEMENS DIMENSION VISTA
- 28. SIEMENS IMMULITE
- 29. SIEMENS STRATUS
- **30. TOSOH AIA-SERIES**
- 31. VITAL DIAGNOSTICS ATAC 8000
- 32. VITAL DIAGNOSTICS ENVOY
- D. Current and Emerging Technologies
- 1. MONOCLONAL AND POLYCLONAL ANTIBODIES
- 2. IMMUNOASSAYS
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)
- Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

- d. Fluorescent Immunoassays
- e. Luminescence
- Chemiluminescence

Bioluminescence



f. Latex Agglutination g. Immunoprecipitation H. Affinity Chromatographu e. Liposome Flow-Injection Immunoassay **3. MOLECULAR DIAGNOSTICS** a. Technology Overview b. Amplification Methods PCR DAP-PCR Immuno-PCR QC-PCR CAR DNA HPA LCR NASBA QBR SDA 3 SR, and others 4. CHROMOSOME ANALYSIS a. Chronic Myelogenous Leukemia (CML) b. Acute Myeloid Leukemia (AML) c. Acute Lymphoblastic Leukemia (ALL) d. Malignant Lymphomas Lymphoid Malignancies e. Chronic Lymphocytic Leukemia (CLL) f. Solid Cancers g. Chromosomal Translocation and Oncogenes **5. ARTIFICIAL INTELLIGENCE** 6. FLOW CYTOMETRY 7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE) 8. BIOSENSORS 9. COMPETING/COMPLEMENTING TECHNOLOGIES a. CT b. MRI c. NMR d. PET e. Photonics Spectroscopy

F. Personal Testing



Germany

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- **B.** Instrumentation
- C. Computers, Software and Automation
- **D. Auxiliary Products**

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
- **1. MARKETING APPROACHES**
- 2. PRODUCT COMPLEXITY
- **3. CUSTOMER PREFERENCE**
- 4. ESTABLISHED SUPPLIERS
- 5. EMERGING SUPPLIERS
- 6. MAJOR TYPES OF DISTRIBUTORS
- 7. MARKET SEGMENTATION FACTOR

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints



G. Decentralized Testing Market Challenges **COMPETITIVE PROFILES** Abbott AdnaGen Applied Gene Technologies Arca Beckman Coulter/Danaher **Becton Dickinson Biomedical Diagnostics** bioMerieux **Bio-Rad** Cepheid **Correlogic Systems** Dako Decode Diadexus Diagnocure Diasorin Eiken Chemical Enterix Enzo Biochem **Epigenomics Exact Sciences** Fujirebio Gen-Probe **Guided Therapeutics** Hologic Ipsogen **Kreatech** Kyowa Medex Life Technologies Mackay Life Sciences Myriad Genetics Nanogen Elitech OncoLab **Otho-Clinical Diagnostics** Panacea Pharmaceuticals **Polartechnics** Polymedco



PreMD Qiagen **Radient Pharmaceuticals** Roche Scienion Sequenom Siemens Healthcare Takara Bio **Targeted Diagnostics & Therapeutics** Tosoh Veridex Wako Pure Chemicals Wallac/PE Zila **APPENDIXES** Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic **Technology and Applications** Appendix II: Assumed Currency Exchange Rates



List Of Tables

LIST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Sub classification Tests **Biochemical Markers Potential Applications In Cancer Diagnosis Oncogenes Potential Applications In Cancer Diagnosis** Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications In Cancer Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis Executive Summary Table: Germany, Hospital Cancer Diagnostic Test Volume and Sales Forecast Germany, Estimated Cancer Death Rates Per 100,00 Population Germany, Hospital Laboratories Performing Cancer Diagnostic Tests Germany, Hospital Laboratories Performing Cancer Diagnostic Tests by Bed Size Germany, Hospital Laboratories, Major Cancer Diagnostic Test Volume Forecast by Test



Germany, Total Cancer Diagnostics Sales By Major Supplier Germany, AFP Testing Market Diagnostics Sales by Major Supplier Germany CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier Germany, CA 19-9 Testing Market Diagnostics Sales by Major Supplier Germany, CA 125 Testing Market Diagnostics Sales by Major Supplier Germany, CEA Testing Market Diagnostics Sales by Major Supplier Germany, PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2015 Strategies in the German Hospital Tumor Marker Testing Market Product link: <u>https://marketpublishers.com/r/20E552ADB8AEN.html</u>

> Price: US\$ 3,080.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/20E552ADB8AEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970